Last reviewed · How we verify
30-day DAPT
30-day DAPT, marketed by St. Antonius Hospital, holds a position in the dual antiplatelet therapy segment with a key composition patent expiring in 2028. The drug's key strength lies in its established market presence and regulatory approval. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | 30-day DAPT |
|---|---|
| Sponsor | St. Antonius Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
- HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN) (PHASE3)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy (NA)
- Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2) (PHASE4)
- Rivaroxaban for Slow Coronary Flow After PCI in STEMI (PHASE4)
- Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 30-day DAPT CI brief — competitive landscape report
- 30-day DAPT updates RSS · CI watch RSS
- St. Antonius Hospital portfolio CI